An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

BACKGROUND: Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA repair,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res
Autors principals: Stringer-Reasor, Erica M., May, Jori E., Olariu, Eva, Caterinicchia, Valerie, Li, Yufeng, Chen, Dongquan, Della Manna, Deborah L., Rocque, Gabrielle B., Vaklavas, Christos, Falkson, Carla I., Nabell, Lisle M., Acosta, Edward P., Forero-Torres, Andres, Yang, Eddy S.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7934554/
https://ncbi.nlm.nih.gov/pubmed/33663560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-021-01408-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars